Clinical Trial Update: Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjunctive pimavanserin for major depressive disorder with inadequate response to antidepressants has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Adjunctive Treatment of Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2021-11-17